0001079974-18-000667.txt : 20181217 0001079974-18-000667.hdr.sgml : 20181217 20181217171421 ACCESSION NUMBER: 0001079974-18-000667 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181031 FILED AS OF DATE: 20181217 DATE AS OF CHANGE: 20181217 EFFECTIVENESS DATE: 20181217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Apotheca Biosciences, Inc. CENTRAL INDEX KEY: 0001632053 STANDARD INDUSTRIAL CLASSIFICATION: METAL MINING [1000] IRS NUMBER: 472055848 STATE OF INCORPORATION: NV FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55467 FILM NUMBER: 181238786 BUSINESS ADDRESS: STREET 1: 10901 ROOSEVELT BLVD., STREET 2: SUITE 1000C CITY: SAINT PETERSBURG STATE: FL ZIP: 33716 BUSINESS PHONE: 727-228-3994 MAIL ADDRESS: STREET 1: 10901 ROOSEVELT BLVD., STREET 2: SUITE 1000C CITY: SAINT PETERSBURG STATE: FL ZIP: 33716 FORMER COMPANY: FORMER CONFORMED NAME: Cannabis Leaf, Inc. DATE OF NAME CHANGE: 20170731 FORMER COMPANY: FORMER CONFORMED NAME: Pacificorp Holdings Ltd. DATE OF NAME CHANGE: 20150128 NT 10-Q 1 apothnt10q10312018.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 12b-25
NOTIFICATION OF LATE FILING

03836L107

000-55467

CUSIP Number

Commission File Number


(Check one):

[ ] Form 10-K    [           ] Form 20-F    [           ] Form 11-K
[ X ] Form 10-Q    [           ] Form 10-D    [           ] Form N-SAR    [           ] Form N-CSR

For Period Ended: October 31, 2018

[           ]

Transition Report on Form 10-K

[           ]

Transition Report on Form 20-F

[           ]

Transition Report on Form 11-K

[           ]

Transition Report on Form 10-Q

[           ]

Transition Report on Form N-SAR

For the Transition Period Ended:

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

APOTHECA BIOSCIENCES, INC.
Full Name of Registrant

CANNABIS LEAF INCORPORATED
Former Name if Applicable

10901 Roosevelt Blvd., Suite 1000C
Address of Principal Executive Office (Street and Number)

Saint Petersburg, Florida 33716
City, State and Zip Code

 


 

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

X

(a)

The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense

 

 

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

 

 

(c)

The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.



PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Registrant requires additional time to file its Form 10-Q so that it can complete the necessary review and compilation of information to file a complete and accurate report.

PART IV — OTHER INFORMATION

(1)

Name and telephone number of person to contact in regard to this notification

 

 

John Verghese

(727)

228-3994

 

(Name)

(Area Code)

(Telephone Number)

 

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

[ X ] Yes [     ] No

 

 

(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

[    ] Yes [ X ] No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 

 


 

 


APOTHECA BIOSCIENCES, INC.
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 17, 2018

By:

/s/ John Verghese

 

 

John Verghese

 

Title:

 Chief Operating Officer